Related Experiment Video
Updated: Jun 22, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Meningococcal C conjugate vaccine: the experience in England and Wales
Helen Campbell1, Ray Borrow, David Salisbury
1Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK. helen.campbell@hpa.org.uk
Abstract:
Meningococcal C conjugate vaccine was introduced in the UK in November 1999 together with a comprehensive meningococcal surveillance strategy to support and inform the vaccine programme. These surveillance data have provided important information on the long-term effectiveness of the programme, through direct and indirect protection, and on the prevalent serotypes and serosubtypes causing invasive meningococcal infection subsequent to vaccine introduction. The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years.
Related Concept Videos
Bacterial Meningitis
Cryptococcal Meningitis
Bacterial Meningitis I: Introduction
Vaccinations
Bacterial Meningitis II: Pathophysiology
Viral Meningitis

